Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers including bladder, blood, colon, head and neck, kidney, liver, lung, melanoma and stomach. Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. MNG Tracker report title “Opdivo/Yervoy Drug Sales & Forecast” provides historical as well as estimated Opdivo/Yervoy sales in Global, United States and Rest of the World market. This is single page report which also covered key factors for the growth/decline of the Opdivo/Yervoy sales in Global, United States and Rest of the World market.
MNG Tracker is a market research company which offer market research reports and database subscription service. Continuous tracking on latest changes in the industry and predict about the emerging needs, challenges and opportunities, is the essential needs for the growth of the business. MNG Tracker is exists for that. MNG Tracker is steadily monitored on the latest happening in the industries, companies and regulatory policies around the world. MNG Tracker is all about market, research and data. We know our clients; who they are, what they see and what they do. MNG Tracker team is fully dedicated to achieve their needs and expectation.
125/5D, Sector 5 Vrindavan Yojna,
Lucknow - 226002, India
Phone:+91 8527886312,
+ 91 7530849871
Email: info@mngtracker.com
FOLLOW USCOPYRIGHT © 2018 MNG Tracker. All Rights Reserved.